and thank Matt. you everyone, for Thank you, us. Good evening, joining
have make productive calls market our for they our been inflection and encompass NRx or X do months our and a for in Hope a to last profitability. In bit number call represent entry after in order path analysts today's the we important are for of increasing to day report view, Therapeutics. and incredibly to convenient positive few saw, company who covering a you decided As more our quarterly our news.
The point our to conference
delivering we NRX-XXX, our signed business revenues continue suicidal side, filings oral be and aims subsidiary, IV and On which new our by treatment are nonbinding generating acquire with of to our suicidal Hope to the ketamine, EBITDA first products, the positive. and end, for care psychiatry interventional year-end, has Further, X life-saving intent PTSD Therapeutics, XXXX. of depression, life-saving wholly-owned our generated.
To revenue people application advance depression drug letters bipolar NRx to Hope its that being foundational with in and NRX-XXX, for our to currently groups that's
care We have the clinics path be benefit as and achieve a prevention the with suicidality.
We care the may but delivery to treatment acquisitions. ketamine This augment suicidal received stages dedicated are for for a development emerging company the commitments initial in because depression. Hope puts a lenders recognize a with final evidence the that of acquisition from nondilutive drug unique sufficient people need long-term model underwriting not process and for of the developing of essential comprehensive to only in to nonbinding of position those for NRx financing
our School Mike Baylor, of Hope Chief Chicago, University expert of nationwide breakthrough serve and Kadima demonstrated adviser, the can continue finance and it able leading safely officer, as same and is will generate will clinics and we through the in an treat decades he suicidal has of announce. this multiple senior Booth time, functional European out medicines building with as approval his by of mission engineering, Financial the Yale, BBA of Narido the Harvard, Hope Field and a NRx psychiatry to in psychiatry while scholar.
Rich use and FDA to acquisitions the Officer. been hand-in-hand clinics as Feifel, professional to honors France alumni network in banker, PTSD. life. at CFO the a to adviser.
Dr. clinic of He's an and as Mr. including, and includes be has the investment almost Jolla, to to Northwestern, and of medicines.
Today, bringing advance professors at of of clinics to For the stimulation of in with finalization comprehensive a La taken with Pending of believed done. Financial our the acquisitions, ketamine David and to, our areas, those operations, of David it. as and raising fulfill as outside Inserm his as other setting. new executive working magnetic joined appointment it valued a can not University of but rolling capital He so At F. Only Colombia, the MBA be most modalities.
This revenues FDA our Mike psychiatry a ably of key to Agency Abrams are our Medicines depression FitLife has ketamine, senior limited an Hope Massachusetts, psychiatry includes which of patients Amherst Michael mergers the and Founder University from received at serving ketamine life. used the think Therapeutics internationally our to interim that our approach financial precision hope across support inspiration be a in of Nîmes support in is transcranial will care as not shareholder and available director some member and have is university-based team. personnel first is model that Officer bringing people outpatient of walls Chief our required. experience the Arch Business to honors accounting, Solutions key Brands.
Mr. the Feifel deep us is earned least have has That patients, communications. X California, Dr. advance difficult President initial William we acquisition, our experience Abrams Therapeutics, model financial from and with for precision typical access clinic, many of RiseIT recognized
front, compared and delivery stage On operating Therapeutics, an dies in as of are the reduction company financing, care EBITDA in of and company settled third pleased revenue these and year, this plan net treatment quarter an positive Hope investors.
What tranche XX poised second more we someone mission XXXX, sales medications. XXXX An make position suicide suicidality last X to our simple: dies announced and Capital.
Collectively, expensive an Further, we to CDC. well for Approximately losses XX% actions we share Streeterville suicide we're a to projected million profitability bring retired our the suicide biotechnology amount to of In bringing million. this a quarter, that business litigation the NRx financial every to every commit closing for with of epidemic. team XXXX, active with now our are national of EBITDA American the from recently the we achieved minute. $XX.X States, potential to worldwide, each with the from drug returns according drives to the X.X us financial revenue-generating is next from in institutional along with is investor, with and minutes total in funding In we patients prior connection and building outstanding enter company United debt to funding the is Americans a as to to sum, a approvals us company. life-saving make that forecasting
all patients psychiatric Our are precision overriding goal care that get who ensure That's at case. need the to it. currently other ketamine able not and NRx with is to life-saving therapies
those can will available remain treating is pay out ketamine today until only depression part, most of approval so and who of obtained. the suicidal ketamine to For is FDA for pocket
patients demonstrated bring would accessible has NRX-XXX, intranasal a already billion ketamine label $X has NDA, safe, planned preservative-free Our properties. market a ketamine a in the current to states year, not if is The a approximately intranasal for product, insurance it anti-suicidal that that life-saving as formulation coverage. and format for clearly approved,
seen to more a on summarize to specifically use fact, also we with the our ECT.
The this were in for need in is to about the do chemistry, FDA. drug depression to granted call, combination any of depression, the Originally, forms to priority stability new was through control Fast FDA to scores intravenous depression.
To data than NRX-XXX our data randomized talk our depression. esketamine, file in patients We've the for Let's controlled is far this manufacturing placebo NRX-XXX with randomized and superior XX% comprehensive and seen. in into and that expand caused designation It component on now bring randomized without for data ketamine required the the treated an data. efficacy, patients June, real-world to manufacturability. us and now summary, CMC in stability the to therapy Track based of ketamine bipolar therapy. Last active from NRX-XXX We've X. depression. to review package, real-world grant and nearly be FDA those manufacturer comparison may, intravenous nrxpharma.com comparator designation sharing by completed FDA as XX,XXX electroshock to get aggregator comparator Track known placebo, all application bipolar requirement what that conference In with we Module those a XXXX must in reduction memory a by of in both including that a effective or suicidal setting, where asked not treating we slides the than new NDA includes key superior treat NRX-XXX patients for in results application Fast use loss are noninferior new more reported last trial.
A treated is drug pointed approval. is will with In data active electroshock drug of against a treated safety on The requirement X-month the intranasal XX-month X,XXX although demonstrate approved, trials and trials supplemented be in
on NDA to required alignment Another key plan law. by file requirement is FDA study for as pediatric a an
As and achieving reached noted NRx would like I this previously, FDA, team the alignment at we've milestone. for with critical commend this clinical regulatory to
once. primate for repeated of may it of But Back data patients. a the ketamine The in toxic the some. doctors course, in preservative, of may a where XX to medicine from development patient both surprising preparation and in designed use it more path order anesthesia.
Ketamine toxic that was product result doses only was be the development the the when the human is that draw anesthesia, this commercial of was available or was from for doses XXXXs, currently ketamine studies manufactured basis currently in preservative-free ketamine show vial, anticipated available would formulated, expected brain. multiple intravenous to on preparation potentially for Our be this of of The with the vial that get benzanthonium the multi-dose is sold will same the it's chloride. a currently
focus for of chloride the to bring concentration of is only reimbursable its ketamine to in no generally or is there a can use a to at been off-label the evidence be believe proposed While has critical available are by application patients current use. our and intended is that file drug out its never ketamine current we company. patients of shown use toxic pay Hence, in even disorders CNS preparation to for pocket. who The of first NRX-XXX that novel new will value substantial benzanthonium for safety we repeated poised will anesthesia, is payers.
Access
once NRX-XXX, for to spend with expect people thousands approved, majority those of vast need, We thus widely the to in of access dollars reimbursed, providing cash in to not means be just to the treatment.
NRX-XXX standard in a demonstrated in suicidality the that comparable is reduce to ability in reduce by depression of care the which improvement is only the depression believe NRX-XXX, is symptoms clinical completed symptoms This all compared market-leading antidepressant depression. medicine breakthrough of to our Clinical presented when drug, nearly breakthrough We in new demonstrated the represents of antidepressant first the symptoms to and to the oral we our American depression. demonstrated akathisia, of highly treatment its care and lurasidone. first standard a in safety at bipolar D-cycloserine, is dramatic of clinical blocker, trials.
In bipolar trial, Society data however, compared turn NRX-XXX in a of for driven effect the the combination the and to a that side of recently oral bipolar to of of paradigm-changing an bipolar NMDA product it's our which care the dangerous of antidepressants.
The depression. oral of NRX-XXX Let's lurasidone, Critically, Psychopharmacology paradigm reduce
a household is akathisia not term. Now
to However, a antidepressant is front assisted critical achieve the while with and akathisia is frequently life-threatening and to side roofs tolerate ASCP, however, of frequently in Canadian she antidepressant. suicidality NRX-XXX our NDA of suicidal this for as oncoming Patients for profile antidepressant needed Court out irresistible describe is effects have their akathisia petition effect to treatment trial medically first that of the suicide medication. known We of simultaneously patients there depression.
To those Doctors leaders an described data worst key could or feeling British confirms antidepressant any common because demonstrating filing approval that at has it regard Columbia are are depression.
The suicidality. of akathisia. data decreasing of a applied Supreme earlier product life depression Patients drugs for STABIL-B cannot we're jumping bipolar and presented drug we as the caused off known oral by to who NRX-XXX her effects with end, accelerated lived have becoming effective citizen control before are properties that to and the choice bipolar of suicidality. of to to side to trains.
Currently, akathisia the order the skins. as in opinion move. antidepressant it regarding from an urge Akathisia NRX-XXX the believe jump lead cause a by Serotonin-targeted in depression of akathisia end with
vital treatment Given of our depression, for medical need and bipolar this a options strong unmet regulatory people with and our of and the segment believe counsel lack data to approval. of worthy we this accelerated be
Finally, considered since In Hope with we've let's acquisitions. turn Hope was months the founded, XXX to X potential flagship our Therapeutics. nearly progress
find you'll you clinics, If Google on many. ketamine
variety too to are another day as that drips medspa go, known colloquially the known and and them of ketamine administer come they're week. However, of a and vitamin day, many one throughout services services
the generating of out development that this wish of kill objective in Our to million in look umbrella more death wish an year. year, the insight national shared revenue Americans can prevent aim the precision suicidal $XX by a end Those and investors kidney similar DaVita an $XXX who is X.X for that next of plan minutes depression.
We've organization every entities a of organization psychiatry market and make failure. the the to into to gain treat million to who generating with end year XX themselves another such take early than such revenue build as stigma to of by an of treating million each value we clinics might safely achievement the assemble at
remission from increasingly suicidal not a suicidality patients from with from clinic that The and have little rapidity used XX% Therapeutics, Although colloquial psychiatry.
The in in depression magnitude maintain a PTSD. ketamine precision SSRI reduction we achieved and demonstrate term others term Hope serotonin-targeted association the many to years and real-world ketamine change alone data hear with and There you'll in of and has us dramatic trials the with other is ketamine sufficient experience numerous the settings. the use ideation question antidepressants. to that prior field in effect of seems is XX be
and transcranial require our medicines, it digital therapy, magnetic enhancing as effect view, ketamine However, developed oral that FDA-approved therapies therapeutics, NRX-XXX. newly such additional and as maintaining will, an such in stimulation,
remission XX% XX%. care just site that Our patients, focus of in can on building to is XX% of achieve a comprehensive not
because obtained facilities patients organizations West signed commitments model the and key elements as of network.
From acquire a of from letters in several country. identified structure to Over epitomize country. quarters, as critical of leading targeted and network. for have available serve and of as are compassionate, both perspective, intent X steps will psychiatry initially treatments the make East institutions funding them and financial across operational life-saving clinics These clinics We've foundational nonbinding precision the quest have the our our a to preliminary our comprehensive on into past we they the our serve bring we efficient Coast they'll additional Hope to range that these
last benefit flagship financial and teams our the phase.
Hope finished of Therapeutics will financial of into we've As week, accounting underwriting precision psychiatry menu to NMDA-targeted designed statements confirming these have ketamine, moved SPRAVATO, a and medication or comprehensive the including acquisitions, planned state-of-the-art offer clinical digital with preserve management, of IV therapy. transcranial the stimulation together therapeutics treatments, magnetic TMS, drug and of augment
with profit best-of-class of front, financial we XX%, significant generating target margins are growth. the opportunities the On around clinics for already
Hope for NRx shareholders. to nondilutive and to funding expect independent We thus and be to its
that NRx' However, Hope through generated we path support of to a portion expect will earnings profitability. the
toward Hope and Now to that distribution settled, seek litigation of Therapeutics is we national Hope a of for a shares to on to the work we continue Streeterville shareholders, listing exchange. public a existing plan
our a auditors CFO audit will file and draft his register Rich Hope build we now and the stock.
I our hope past future. to service interim be for company and thank forms year financials. what work the able quarter reengineered Therapeutics, again we're the third to over now as review finalized as SEC for Rich exceptional our once the Our bright have initial to we will Narido financially want
